BLLN: Clean Q3 Beat, But the Evidence Does Not Yet Price a Side, So WATCH
Published · entry price $113.89 · machine-generated by the QuantLogix Thesis Engine and graded publicly at T+7/30/90 days · BLLN charts & signals →
BillionToOne printed a 47% revenue beat-and-raise with GAAP profitability, and BTIG kept a $130 target, but the stock already trades near 11.5x guided sales at $113.89. Technicals are split (MACD negative, SMA trend bullish), the platform consensus (Strong Sell, $59.93) conflicts with the sell-side print I can verify, and the engine's Healthcare Strong Buy cohort averages only +1.18%, below the +5% bar. Probability-weighted value is about $113, so there is no edge in either direction. A close above $130 or below $98 within 30 trading days would change the call.
Options expression
Thesis
- BLLN closes below $98.00 within 30 trading days, which would erase the post-earnings gap, undercut the beat-and-raise as a support, and move this WATCH toward bearish.
- BLLN closes above $130.00 within 30 trading days, reaching the BTIG target and confirming the engine's Strong Buy read, which would move this WATCH toward bullish.
- BLLN holds above $102.73, the platform's reference price, which I read as the pre-earnings level, and so keeps the post-earnings gap (about +10.9%) intact through the window. — triggered 11/05/2026
Evidence Graph3 of 3 claims linked · 5 preserved sources
This graph uses only evidence frozen into the thesis at publication on 11/05/2026. “Retrieved source passage” is the preserved grounding excerpt the engine saw; “published note passage” is thesis context, not a source quote. Missing edges and dates remain visible.
BLLN closes below $98.00 within 30 trading days, which would erase the post-earnings gap, undercut the beat-and-raise as a support, and move this WATCH toward bearish.
Strong Q3 growth and a raised guide argue against a close this far below the current price, so a break would contradict the fundamental print.
Retrieved source passage
BillionToOne (BLLN) Q3 2026 Earnings Call Transcript & Audio Earnings Call: Q3 2026 Nov 4, 2026 Summary Q3 revenue rose 47% YoY to $123.0M, with 71% gross margin and an 18% adjusted EBITDA margin. FY 2026 revenue guidance was raised to $460M-$470M, while Northstar Clear is set to launch December 15. Operator I would now like to hand the conference over to your speaker today, Gabby Capell with Investor Relations. Gabby Capell Investor Relations Representative, BillionToOne Good afternoon, everyone. Thank you for participating in today's conference call. Joining me on the call from BillionToOne, we have Ozan Atay, Co-Founder and Chief Executive Officer, and Ross Taylor, Chief Financial Offic
Reports the $113.89 price and $5.37B market cap, which anchor how far $98 is from spot.
Retrieved source passage
BTIG reiterates Buy on BillionToOne stock, keeps $130 target By Investing.com BTIG reiterates Buy on BillionToOne stock, keeps $130 target Published Nov 05, 2026, 06:14 AM © Reuters Investing.com - BTIG maintained its Buy rating and $130 price target on BillionToOne Inc (NASDAQ:BLLN) shares following the company’s third-quarter earnings report. The stock currently trades at $113.89, giving the company a market capitalization of $5.37 billion. BillionToOne reported third-quarter revenue that exceeded expectations by 6%, driven by 47% year-over-year revenue growth and 96% year-over-year growth in its oncology business. The company’s revenue growth over the last twelve months reached 90%, whi
BLLN closes above $130.00 within 30 trading days, reaching the BTIG target and confirming the engine's Strong Buy read, which would move this WATCH toward bullish.
BTIG reiterated Buy with a $130 target after the print, which marks a credible upside level.
Retrieved source passage
BTIG reiterates Buy on BillionToOne stock, keeps $130 target By Investing.com BTIG reiterates Buy on BillionToOne stock, keeps $130 target Published Nov 05, 2026, 06:14 AM © Reuters Investing.com - BTIG maintained its Buy rating and $130 price target on BillionToOne Inc (NASDAQ:BLLN) shares following the company’s third-quarter earnings report. The stock currently trades at $113.89, giving the company a market capitalization of $5.37 billion. BillionToOne reported third-quarter revenue that exceeded expectations by 6%, driven by 47% year-over-year revenue growth and 96% year-over-year growth in its oncology business. The company’s revenue growth over the last twelve months reached 90%, whi
The press release confirms 47% revenue growth and the raised FY2026 guide that would underpin a re-rating.
Retrieved source passage
BillionToOne Reports Third Quarter 2026 Results and Raises 2026 Revenue Guidance MENLO PARK, CA, November 4, 2026 - BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for the third quarter ended September 30, 2026 and raised guidance for full year 2026. Financial Highlights: ● Total revenue of $123.0 million in the third quarter of 2026, compared to $83.5 million in the third quarter of 2025, an increase of 47%. ● Prenatal clinical testing revenue was $104.3 million in the third quarter of 2026, an increase of 41% from the third quarter of 2025
Summarizes the guide raise and the Dec 15 Northstar Clear launch, a catalyst inside the 30-day window.
Retrieved source passage
BillionToOne raises 2026 revenue outlook to $460M-$470M while launching Northstar Clear on December 15 (NASDAQ:BLLN) Seeking Alpha BillionToOne raises 2026 revenue outlook to $460M-$470M while launching Northstar Clear on December 15 Nov 04, 2026, 11:25 PM ET BillionToOne, Inc. (BLLN) Stock AI-Generated Earnings Calls Insights Earnings Call Insights: BillionToOne (BLLN) Q3 2026 Management View - "In the third quarter, we executed on every one of our 4 pillars. It was another strong quarter. We delivered record revenue and a combination of rapid growth and GAAP profitability" (Co-Founder, Chairman & CEO Oguzhan Atay).
BLLN holds above $102.73, the platform's reference price, which I read as the pre-earnings level, and so keeps the post-earnings gap (about +10.9%) intact through the window.
Q3 revenue of $123.0M (+47% YoY), 71% gross margin and the raised guide give a fundamental reason for the gap to hold.
Retrieved source passage
BillionToOne (BLLN) Q3 2026 Earnings Call Transcript & Audio Earnings Call: Q3 2026 Nov 4, 2026 Summary Q3 revenue rose 47% YoY to $123.0M, with 71% gross margin and an 18% adjusted EBITDA margin. FY 2026 revenue guidance was raised to $460M-$470M, while Northstar Clear is set to launch December 15. Operator I would now like to hand the conference over to your speaker today, Gabby Capell with Investor Relations. Gabby Capell Investor Relations Representative, BillionToOne Good afternoon, everyone. Thank you for participating in today's conference call. Joining me on the call from BillionToOne, we have Ozan Atay, Co-Founder and Chief Executive Officer, and Ross Taylor, Chief Financial Offic
Shows the post-earnings price of $113.89 against which the gap is measured.
Retrieved source passage
BTIG reiterates Buy on BillionToOne stock, keeps $130 target By Investing.com BTIG reiterates Buy on BillionToOne stock, keeps $130 target Published Nov 05, 2026, 06:14 AM © Reuters Investing.com - BTIG maintained its Buy rating and $130 price target on BillionToOne Inc (NASDAQ:BLLN) shares following the company’s third-quarter earnings report. The stock currently trades at $113.89, giving the company a market capitalization of $5.37 billion. BillionToOne reported third-quarter revenue that exceeded expectations by 6%, driven by 47% year-over-year revenue growth and 96% year-over-year growth in its oncology business. The company’s revenue growth over the last twelve months reached 90%, whi
Unmapped source register
1 sourceThese links were preserved in the note but cannot be honestly assigned to a specific claim.
Published note passage
The platform flagged BLLN as a 100/100 Strong Buy on [2026-06-26].
What changed
Complete, timestamped thesis history.
-
1 monitored claim triggeredBLLN continues to hold its post-earnings gains above the $102.73 reference level, maintaining the gap established during the third quarter report. Consequently, the thesis remains open with the original "WATCH" verdict in effect as the stock trades at $113.89. · $113.89
-
Thesis publishedWATCH · LOW conviction
Setup
BillionToOne (BLLN) is a molecular diagnostics company. Prenatal testing is about 85% of revenue ($104.3M of $123.0M in Q3), and oncology is the fast-growing second leg. The stock trades at $113.89 with a $5.37B market cap (Investing.com). On the midpoint of FY2026 guidance ($465M), that is roughly 11.5x market-cap-to-sales, before adjusting for cash or debt, which the retrieved sources do not give.
My call is WATCH, low conviction. The business is executing. What is missing is a mispricing I can defend against the platform's own graded record.
Evidence & Data
Fundamentals (supports the long side). Q3 revenue was $123.0M, +47% YoY against $83.5M a year ago. Prenatal grew 41%, gross margin was 71%, and adjusted EBITDA margin was 18% (about $22M). FY2026 guidance rose to $460M-$470M, and Northstar Clear launches December 15 (press release; call transcript). BTIG says revenue beat expectations by 6% and oncology grew 96% (Investing.com).
Analyst consensus (challenges the long side, but is thin). The platform shows Strong Sell with a $59.93 target, about 47% below spot. The only sell-side datapoint I can verify is BTIG's Buy and $130 target (Seeking Alpha). The platform consensus also references a $102.73 price, which looks stale. I cannot verify the analyst count or dates, so I discount it but do not dismiss it. Even a few stale sell-side targets set a valuation ceiling.
Technicals (mixed). RSI is 49.3, which is neutral. MACD is -1.118, which is bearish. The 5-day momentum of +7.67% against -7.17% over 20 days is a bounce inside a drawdown. The SMA trend reads bullish. These readings do not agree, so they carry little weight.
News sentiment. The score is 0.296, mildly positive and consistent with a clean print. At that level it is not a differentiated signal.
Macro. The retrieved sources contain no rates or sector-rotation data, so I will not cite numbers. The structural point is that a high-multiple, recently profitable growth name is sensitive to real yields and to the rotation between defensive and growth healthcare. That is a risk I cannot size from the evidence, so it adds to my caution.
Base rates. Healthcare Buy signals average +3.03% over 392 resolved signals. The narrower Healthcare × engine Strong Buy cohort averages +1.18% over 213 signals, with a 95% CI low of -1.09%, and fails the +5% bar. The engine's own win probability on BLLN is 50%. Directional calls have been right 7 of 19 times, and 6 of the last 7 theses were invalidated on their own claims. The platform flagged BLLN as a 100/100 Strong Buy on 2026-06-26. I have no graded outcome for that call.
Consensus vs. variant view. The consensus, if the Strong Sell is real, is that BLLN's valuation embeds perfection and the stock should mean-revert toward $60. The visible sell-side and the engine say growth justifies a premium. I think both camps are missing the same thing: at 11.5x sales and a 47% growth rate, the debate is about duration of growth, and one quarter does not settle it. I reject the $59.93 target because it implies a roughly 50% cut for a company that just raised guidance and is GAAP profitable. I also reject chasing the engine's Strong Buy, because that cohort has not shown an edge. Neither side is mispriced enough to act on.
Scenario Analysis
| Scenario | Probability | Price path | Thesis impact |
|---|---|---|---|
| Re-rating: Northstar Clear launch and further guide raises | 25% | $140 (above BTIG's $130) | Confirms engine; flips toward bullish |
| Digestion: range-bound as the gap is absorbed | 40% | $118 | Keeps WATCH |
| Mean reversion: growth-multiple compression, gap filled | 35% | $88 | Supports the sell-side skeptics; WATCH leans bearish |
EV = 0.25×$140 + 0.40×$118 + 0.35×$88 = $35.0 + $47.2 + $30.8 = $113.0, about -0.8% vs current.
The expected value equals the price, so the odds offer no edge. My 35% weight on the downside reflects the consensus gap and the negative MACD. A thin expected return does not justify a directional call under a +5% bar.
Catalysts & Risks
| Item | Date | Direction |
|---|---|---|
| Northstar Clear launch | Dec 15, 2026 | Upside if early uptake is visible |
| Q4 print against $460M-$470M guide | Not in retrieved sources | Two-sided |
| Rates / growth-healthcare rotation | Ongoing | Downside if yields rise |
| Reimbursement and payer risk in prenatal testing | Not in retrieved sources | Downside, unquantified |
Prenatal concentration (about 85% of revenue) is the main risk. Oncology growing at 96% is the upside optionality, but it is a small base. I have no data on cash, debt, share count or insider selling, and those gaps are why conviction stays low.
What Changes Our Mind
- Toward bullish: a close above $130 within 30 trading days, or an upward guide revision ahead of the Q4 print, with MACD turning positive.
- Toward bearish: a close below $98, about -14% from here, which would erase the gap and put the Strong Sell consensus in play. The short-side cohort is verified at 46.7% win, but bearish calls against the engine's reads have been right only 30% of the time, so I would need the price break first.
- Neutral confirmation: the stock holds above $102.73, the platform's reference price (which I take to be the pre-earnings level), and below $130 through the Northstar launch. That keeps the WATCH.
This is educational market commentary, not investment advice.
Related QuantLogix coverage
- WYHG Rips 194% Today as 81/100 Composite Flips Strong Buy | QuantLogix
- WYHG Flips to 100/100 Strong Buy After 194% Surge | QuantLogix
- BLLN Hits Perfect 100/100 — Signal Engine Flags Strong Buy | QuantLogix
- $MOD Scores 100/100 as Only 31% of Market Advances | QuantLogix
More from QL Research
- OKE · WATCH — ONEOK (OKE): Fundamental Acceleration Meets a Paid-For Tape — WATCH with a $97.50/$86.00 Trigger
- OURA · WATCH — OURA (Private) — The Bookbuild That Wasn't: A Pulled $2.2bn IPO Is a Price Signal Without a Price
- COST · WATCH — COST at $1,012: Elite Operator, Fully Priced Tape — WATCH With Two Hard Triggers
- SQQQ · WATCH — SQQQ: The Decay Is the Trade — A -3x Swap Book With Negative 30-Session EV and No Confirmed Trend
- TLX · WATCH — TLX: A Bull Story On A Bear Tape — The Engine Is Right To Wait
- BDX · WATCH — BDX at $197.88: Strong-Buy Engine Read Meets a Sub-Alpha Cohort and an Overbought Bounce in a Bearish Trend — WATCH, Triggers at $185/$210